Interestingly, SFK inhibitors reduced the viability of FLT3-ITD+ murine AML cells, thus suggesting a therapeutic role for this class of inhibitors in the treatment of the disease [95]. This evidence concerns the gene FLT3 and acute myeloid leukemia.